Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Calif. , May 5, 2015  23andMe, Inc., ... of the Lupus Research Study in collaboration ... individuals with systemic lupus erythematosus, more commonly known as ... genetics of lupus. The effort is also in collaboration ... Lupus Awareness Month in May. Approximately 1.5 ...
(Date:5/5/2015)... AVIV, Israel , May 5, 2015 /PRNewswire/ ... the Company was approved to continue trading on ... OTCQB Marketplace allows for a ... electronic broker-dealers. Investors can have real-time quotes and ... The OTCQB Marketplace includes U.S. ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
(Date:5/5/2015)... Calif. , May 5, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... Credit Suisse Antibody Day in New York ... 6. Dr. McCarthy will present an overview of CytomX,s ... Probody drug conjugate programs. About CytomX Therapeutics ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... CINCINNATI, July 27 Kendle (Nasdaq: KNDL ... Stephen Cutler, PhD, as the Company,s new Senior Vice President ... to Kendle more than 20 years of senior management and ... position the Company for continued growth as a top-tier global ...
... MYERS, Fla., July 28 NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM ... for the second quarter of 2009. , , Highlights: ... $7.5 million , Revenue increased 8% sequentially compared with ... quarter , Major new initiative to develop a Melanoma ...
... (July 27, 2009) -- New video showing the atom-by-atom ... grow, much like the halting motion of a mechanical ... at France,s Universit Lyon1/CNRS and Houston,s Rice University, the ... carbon atoms are added to growing nanotubes. ...
Cached Biology Technology:Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 2Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 3NeoGenomics Reports Second Quarter 2009 Results 2NeoGenomics Reports Second Quarter 2009 Results 3NeoGenomics Reports Second Quarter 2009 Results 4NeoGenomics Reports Second Quarter 2009 Results 5NeoGenomics Reports Second Quarter 2009 Results 6NeoGenomics Reports Second Quarter 2009 Results 7NeoGenomics Reports Second Quarter 2009 Results 8NeoGenomics Reports Second Quarter 2009 Results 9Video shows nanotube spins as it grows 2
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... families, and twin studies suggest that this is largely due ... have been identified as risk factors for obesity but previous ... high level of heritability in childhood obesity, as together they ... This has led to a problem of ,missing heritability,. ...
... levels of vitamin D can help people breathe better and ... study accepted for publication in The Endocrine Society,s Journal ... The study of more than 10,000 Korean adults found that ... into their bodies. Vitamin D is absorbed primarily through sunlight, ...
... experience a "moderate" red tide this spring and summer, report ... the Gulf of Maine. The "red tide" is caused by ... that can cause paralytic shellfish poisoning (PSP). Red tide ... Maine coast. This year,s outlook is similar to the ...
Cached Biology News:Study finds strong genetic component to childhood obesity 2Vitamin D benefits breathing in tuberculosis patients 2Researchers issue forecast for 'moderate' New England red tide in 2013 2
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Request Info...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
... Features Convenient platform for tube ... - 96 x 0.2ml V-bottom tubes ... Thermo-Tube Plates - Thermo-Fast® 96 Non-Skirted ... - 48 x 0.5ml Thermo-Tubes Multiple ...
Biology Products: